CMND ▼ -2.6% - Clearmind Medicine Inc. $CMND - Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled Clearmind Medicine shares declined 2.6% today despite announcing progress on its CMND-100 Phase IIa trial for alcohol use disorder treatment, with enrollment now at one-third capacity for Part C of the study. The pullback suggests investors may have interpreted the milestone as incrementally slower than expected or were taking profits following recent moves. 01-SEP-2026 07:37 AM ET